139 related articles for article (PubMed ID: 9718761)
21. Is epoetin alfa a treatment option for chemotherapy-related anemia in children?
Büyükpamukçu M; Varan A; Kutluk T; Akyüz C
Med Pediatr Oncol; 2002 Oct; 39(4):455-8. PubMed ID: 12203663
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
Durmaz O; Demirkaya M; Sevinir B
Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
[TBL] [Abstract][Full Text] [Related]
23. [Recombinant erythropoietin (r-HuEPO) in the treatment of anemia in multiple myeloma].
Spicka I; Haber J; Petruzelka L; Kolesková E; Sálková J; Straub J; Zounar R; Klener P
Cas Lek Cesk; 1996 Jul; 135(14):450-3. PubMed ID: 8925545
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human erythropoietin in anemia of prematurity.
Whitehall JS; Patole SK; Campbell P
Indian Pediatr; 1999 Jan; 36(1):17-27. PubMed ID: 10709119
[TBL] [Abstract][Full Text] [Related]
25. Erythropoietin (r-HuEPO) in the treatment of anemia of nodular sclerosis type Hodgkin's disease--a preliminary report.
Wojtukiewicz MZ; Sawicki Z; Radziwon P
Rocz Akad Med Bialymst; 2000; 45():145-9. PubMed ID: 11712426
[TBL] [Abstract][Full Text] [Related]
26. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
27. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
28. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
29. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
Granetto C; Ricci S; Martoni A; Pezzella G; Testore F; Mattioli R; Lampignano M; Tacconi F; Porrozzi S; Gasparini G; Mantovani G;
Oncol Rep; 2003; 10(5):1289-96. PubMed ID: 12883695
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy.
Massa E; Madeddu C; Lusso MR; Gramignano G; Mantovani G
Crit Rev Oncol Hematol; 2006 Feb; 57(2):175-82. PubMed ID: 16213740
[TBL] [Abstract][Full Text] [Related]
31. [High-dose induction therapy followed by maintenance with recombinant human erythropoietin for 30 patients with tumor-related anemia].
Xu F; Zhang L; Xiang XJ; Wang ZQ; Zhou ZM; Wang SY
Ai Zheng; 2006 Sep; 25(9):1120-2. PubMed ID: 16965653
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia.
Tzekova V; Mihaylov G; Elezovic I; Koytchev R;
Curr Med Res Opin; 2009 Jul; 25(7):1689-97. PubMed ID: 19505200
[TBL] [Abstract][Full Text] [Related]
33. Erythropoietic response induced by recombinant human erythropoietin in anemic cancer patients candidate to major abdominal surgery.
Braga M; Gianotti L; Gentilini O; Vignali A; Di Carlo V
Hepatogastroenterology; 1997; 44(15):685-90. PubMed ID: 9222672
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors.
León P; Jiménez M; Barona P; Sierrasesúmaga L
Med Pediatr Oncol; 1998 Feb; 30(2):110-6. PubMed ID: 9403020
[TBL] [Abstract][Full Text] [Related]
35. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events.
Rosenzweig MQ; Bender CM; Lucke JP; Yasko JM; Brufsky AM
J Pain Symptom Manage; 2004 Feb; 27(2):185-90. PubMed ID: 15157043
[TBL] [Abstract][Full Text] [Related]
36. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
[TBL] [Abstract][Full Text] [Related]
37. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
38. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
Biesma B; van de Werf PR; Melissant CF; Brok RG
Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
[TBL] [Abstract][Full Text] [Related]
39. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.
Malik IA; Khan ZK; Hakimali A; Sabih M; Rehman G
J Pak Med Assoc; 1998 May; 48(5):127-31. PubMed ID: 9813972
[TBL] [Abstract][Full Text] [Related]
40. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
Cazzola M; Ponchio L; Pedrotti C; Farina G; Cerani P; Lucotti C; Novella A; Rovati A; Bergamaschi G; Beguin Y
Haematologica; 1996; 81(5):434-41. PubMed ID: 8952157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
